HC Wainwright reaffirmed their buy rating on shares of Aligos Therapeutics (NASDAQ:ALGS – Free Report) in a research note published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $75.00 price objective on the stock.
Aligos Therapeutics Stock Performance
Aligos Therapeutics stock opened at $7.21 on Wednesday. The company’s fifty day moving average price is $10.75 and its 200 day moving average price is $13.69. Aligos Therapeutics has a 1 year low of $6.76 and a 1 year high of $30.00. The stock has a market capitalization of $563.17 million, a P/E ratio of -5.63 and a beta of 2.16.
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.00) by $4.75. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. The firm had revenue of $1.06 million for the quarter. During the same period in the prior year, the business posted ($10.75) EPS. Sell-side analysts predict that Aligos Therapeutics will post -8.2 EPS for the current year.
Institutional Investors Weigh In On Aligos Therapeutics
Aligos Therapeutics Company Profile
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
Further Reading
- Five stocks we like better than Aligos Therapeutics
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Investing in Travel Stocks Benefits
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Earnings Per Share Calculator: How to Calculate EPS
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.